291 related articles for article (PubMed ID: 17455313)
1. Use of imatinib mesylate in a 15-month old with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia.
Richardson MW; Grewal SS
Pediatr Blood Cancer; 2008 Jan; 50(1):186. PubMed ID: 17455313
[No Abstract] [Full Text] [Related]
2. [Chronic myeloid leukemia and imatinib mesylate therapy].
Chrobák L
Vnitr Lek; 2004 Jan; 50(1):10-2. PubMed ID: 15015223
[No Abstract] [Full Text] [Related]
3. [Treatment of chronic myeloid leukemia with imatinib in the accelerated stage of the disease].
Bulum J; Labar B; Mikulić M; Bogdanić V; Sertić D; Nemet D; Krecak-Gverić V; Kovacević J; Serventi-Seiwerth R; Mrsić-Davidović S; Zadro R; Boban D
Lijec Vjesn; 2003; 125(7-8):176-9. PubMed ID: 14692090
[TBL] [Abstract][Full Text] [Related]
4. CML: imatinib mesylate (Glivec) or something else?
Ghosh A
Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
[No Abstract] [Full Text] [Related]
5. Imatinib and chronic-phase leukemias.
Boros LG; Lee WN; Cascante M
N Engl J Med; 2002 Jul; 347(1):67-8. PubMed ID: 12097546
[No Abstract] [Full Text] [Related]
6. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Drummond MW; Holyoake TL
Cancer; 2003 Oct; 98(8):1776-7; author reply 1777-8. PubMed ID: 14534900
[No Abstract] [Full Text] [Related]
7. Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.
Arancibia AM; Bendit I; Epelman S
Pediatr Blood Cancer; 2008 May; 50(5):1078. PubMed ID: 18085674
[No Abstract] [Full Text] [Related]
8. Update on the use of imatinib mesylate.
Sawyers CL
Clin Adv Hematol Oncol; 2005 Oct; 3(10):757-8. PubMed ID: 16258483
[No Abstract] [Full Text] [Related]
9. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.
Druker BJ
Oncogene; 2002 Dec; 21(56):8541-6. PubMed ID: 12476300
[No Abstract] [Full Text] [Related]
10. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Goldman JM; Melo JV
N Engl J Med; 2001 Apr; 344(14):1084-6. PubMed ID: 11287980
[No Abstract] [Full Text] [Related]
11. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Cortes J; Kantarjian H
Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
[TBL] [Abstract][Full Text] [Related]
12. Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia.
Ossard-Receveur A; Bernheim A; Clausse B; Danglot G; Fauvet D; Leon B; Lozach F; Bories D; Brouzes C; Bourhis JH; Turhan AG
Cancer Genet Cytogenet; 2005 Dec; 163(2):189-90. PubMed ID: 16337868
[No Abstract] [Full Text] [Related]
13. Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib.
Bornhäuser M; Pursche S; Bonin M; Freiberg-Richter J; Jenke A; Illmer T; Ehninger G; Schleyer E
J Clin Oncol; 2005 Jun; 23(16):3855-6; author reply 3857-8. PubMed ID: 15923584
[No Abstract] [Full Text] [Related]
14. [Results of clinical studies on a selective inhibitor of ABL tyrosine kinase (STI571) in patients with Ph(+) leukemia].
Ohnisi K
Rinsho Ketsueki; 2002 Apr; 43(4):235-8. PubMed ID: 12043198
[No Abstract] [Full Text] [Related]
15. Chronic myeloid leukemia in a patient with chronic idiopathic thrombocytopenic purpura: rapid response to imatinib mesylate (STI571).
Imashuku S; Morimoto A; Kuriyama K; Kano G; Hibi S; Todo S
Med Pediatr Oncol; 2003 Aug; 41(2):159-60. PubMed ID: 12825226
[No Abstract] [Full Text] [Related]
16. Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003.
Marcucci G; Perrotti D; Caligiuri MA
Clin Cancer Res; 2003 Apr; 9(4):1248-52. PubMed ID: 12684391
[No Abstract] [Full Text] [Related]
17. Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML).
Tsapas A; Vlachaki E; Sarigianni M; Klonizakis F; Paletas K
Leuk Res; 2008 Apr; 32(4):674-5. PubMed ID: 17920117
[No Abstract] [Full Text] [Related]
18. Regression of cutaneous squamous cell carcinoma in a patient with chronic myeloid leukaemia on imatinib mesylate treatment.
Kawakami Y; Nakamura K; Nishibu A; Yanagihori H; Kimura H; Yamamoto T
Acta Derm Venereol; 2008; 88(2):185-6. PubMed ID: 18311459
[No Abstract] [Full Text] [Related]
19. [Anti-tyrosine kinase: the beginning of molecular therapies of cancer and initial results].
Guilhot F
Bull Cancer; 2001 Jul; 88(7):659-60. PubMed ID: 11495817
[No Abstract] [Full Text] [Related]
20. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
